7 emergency general surgeries account for 80% of admissions, deaths, costs

Researchers looking at data on urgent or emergency general surgery (EGS) operations in the U.S. have found seven types of procedures account for more than 80 percent of all admissions, deaths, complications and costs related to EGS.

The study, published April 27 in JAMA Surgery, examined a federal database of 421,476 patient encounters with EGS between 2008 and 2011. The seven most common procedures are: 

  • Partial colectomy
  • Small-bowel resection
  • Cholecystectomy
  • Operative management of peptic ulcer disease
  • Lysis of peritoneal adhesions
  • Appendectomy
  • Laparotomy

Because only a handful of procedures are responsible for most admissions, deaths and complications, the study concluded “[n]ational quality benchmarks and cost reduction efforts should focus on these common, complicated and costly EGS procedures.”

More than three million Americans are admitted to hospitals every year for EGS diagnoses. Individuals undergoing EGS operations have a mortality rate eight times higher than patients undergoing the same procedures electively.

In the face of such troubling statistics, researchers emphasized the importance of establishing surgical benchmarks for EGS procedures that currently do not exist.

“A more focused, clinically relevant and nationally representative list of EGS procedures is needed,” the researchers wrote. “The goal of the present study was to expand the current diagnosis-based definition of EGS to define a standardized, representative set of procedures that make up the bulk of the national clinical burden of EGS.”

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.